Opening question: When a research-peptide catalog flashes a Genomics England PanelApp gene panel, a “Green gene,” NHS Genomic Medicine Service screenshot, or rare-disease panel badge next to a vial SKU, how do you tell a public gene-panel curation record from proof that the peptide is cleared for people?
Short answer: open the live Genomics England PanelApp site and its Panels listing. PanelApp publishes gene panels related to genomic tests in the NHS National Genomic Test Directory and virtual panels used in the 100,000 Genomes Project; not every gene or panel shown is available for NHS Genomic Medicine Service (GMS) testing. That is clinical-genomics panel literacy. It is not a drug-approval system, and a PanelApp screenshot next to a research peptide does not mean the SKU is gene-panel–validated as a medicine or safe to use.
A practical PanelApp checklist when ads lean on panel graphics:
- Panel vs product scope: PanelApp organizes curated gene (and related) panels for genomic testing pathways. Those panels help clinicians and scientists interpret which genes have diagnostic-level evidence for specified rare-disease or cancer contexts—not whether a research peptide may be sold or injected as a therapy.
- Green evidence level ≠ peptide clearance: The site explains that “Green” (diagnostic evidence level) genes on GMS panels are those analysed as part of the diagnostic pathway for signed-off panels. A green badge is gene–disease panel curation, not manufacturing or medicine authorization for a catalog SKU.
- Not all panels are orderable: PanelApp notes that not all genes and panels shown are available to choose for NHS GMS testing; NHS users should check the separate NHS GMS Panels Resource for signed-off, orderable content. An ad that flashes any PanelApp page may be showing research or historical virtual panels, not a prescribing pathway for peptides.
- Technology limits still apply: PanelApp flags that some genes (for example certain non-coding, mitochondrial, or hard-to-sequence regions) may not be accurately analysed via GMS whole-genome services. Database caveats are genomics literacy—they do not authorize research chemicals.
- What to open next: Resolve the claimed panel and gene evidence level on the live PanelApp site, check whether it relates to the advertised molecule at all, then ask whether the seller is teaching panel literacy or decorating a research-only listing.
None of those steps turns a laboratory research listing into an approved medicine. Company research-only catalogs document laboratory intent and paperwork such as certificates of analysis; they do not create human-use approval. For company facts only—not clinical evidence—Apollo Peptides states products are for laboratory research only, not for human or veterinary use, and describes third-party testing with certificates of analysis.
Bottom line: Use PanelApp to understand how NHS-related gene panels and evidence levels are organized for genomic testing, then ask whether the ad is teaching that distinction or implying a research peptide is medically meaningful because a green-gene screenshot looks clinical. That habit changes what you notice in catalogs—it is not advice to buy, inject, or dose any peptide.
By The Everyday Brief · AI-assisted editorial. Drafted with AI research assistance; claims checked against Genomics England PanelApp home and Panels listing (fetched 2026-09-27 PT). No invented studies, quotes, or dosing. Not medical or legal advice.
Sources
3. GitHub — genomicsengland/PanelApp
4. Apollo Peptides (company facts only)
Related reading
What ClinGen gene-disease validity means when peptide ads flash clinical-genome screenshots
What ClinVar records mean when peptide ads flash variant classifications
What Mondo disease ontology terms mean when peptide ads flash disease IDs